MediSync
AI-powered clinical decision support
Immediate due diligence
Tier 1: High Conviction
Efficient growth and deep moats
Recommended Action
Immediate due diligence
MediSync's platform provides real-time clinical decision support powered by advanced AI, helping healthcare providers deliver better patient outcomes while reducing diagnostic errors by up to 40%.
Weight: 30%
85.0
Founder-Market Fit + Revenue Velocity
Weight: 30%
80.0
Burn Multiple + LTV/CAC
Weight: 25%
95.0
Proprietary Data + Integration Depth
Weight: 15%
75.0
NRR + K-Factor
15 yrs domain exp + serial exit
95% YoY ARR Growth
1.34x (Net Burn / Net New ARR)
7.1x ($320K / $45.0K)
92% private data
8.5 avg APIs per user
132% NRR
0.53 (1.4 invites x 38% conv)
Dr. Rachel Kim
CEO & Co-Founder
Former Chief Medical Officer at Mayo Clinic
Dr. Michael Foster
CTO & Co-Founder
Stanford AI Lab, 20+ publications
Jennifer Walsh
COO
Former VP Operations at Epic Systems
Revenue (ARR)
$52M ARR
+95% YoY
Gross Margin
82%
Burn Rate
$2.8M/month
Runway
30 months
LTV
$320,000
CAC
$45,000
Lead Investors
- FDA-cleared platform with proven clinical outcomes
- Deployed in 450+ hospitals across the US
- Reduced misdiagnosis rates by 40% in clinical trials
- Strong IP portfolio with 12 granted patents
- Healthcare regulatory compliance complexity
- Long sales cycles in healthcare
- Reimbursement uncertainty